Clozapine Immunoassay
Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.
1 . An immunoassay for detecting clozapine in a sample comprising providing a mixture of a) said sample, b) an antibody selectively reactive with clozapine and not substantially cross-reactive with N-desmethylclozapine and clozapine-N-oxide, and c) a conjugate of a carrier having either a reactive thiol or amino group with a compound of the formula:
wherein B is: —(C═O)—, —(C═O)—NH—, —(C═O)—O—, —CH 2 —;
Y is an organic spacing group;
X is a terminal functional group capable of binding to a polyamine polymer; and
p is an integer from 0 to 1;
or salts thereof;
causing the clozapine in the sample and said conjugate in said mixture to bind with said antibody and thereafter measuring the amount of said conjugate in said mixture which is bound or unbound to said antibody whereby the presence of clozapine in the sample can be determined.
2 . The process of claim 1 , wherein the sample is a human sample.
3 . The immunoassay of claim 2 , wherein said antibody is generated from an immunogen comprising an immunogenic carrier having a reactive thiol or amino group conjugated to a compound of the formula:
wherein B is: —(C═O)—, —(C═O)—NH—, —(C═O)—O—, —CH 2 —;
Y is an organic spacing group;
X is a terminal functional group capable of binding to a polyamine polymer; and
p is an integer from 0 to 1;
or salts thereof.
wherein p, X, Y and A are as above.
4 . The immunoassay of claim 3 , wherein the carrier contains a thiol group and X is the compound which is linked to the immunogenic polymer is a functional group capable of reacting with said thiol.
5 . The immunoassay of claim 4 , wherein X is
6 . The immunoassay of claim 5 , wherein Y is lower alkylene.
7 . The immunoassay of claim 6 wherein the immunogenic carrier contains as the functional group
wherein v is an integer from 1 to 6.
8 . The immunoassay of claim 2 , wherein the antibody is attached to a solid support.
9 . The immunoassay of claim 8 , wherein the solid support is microtiter plates.
10 . The immunoassay of claim 9 , wherein the solid support is nanoparticles.
11 . An antibody which binds selectively to clozapine and does not substantially bind to N-desmethylclozapine and clozapine-N-oxide.
12 . The antibody of claim 11 , wherein said antibody is derived from mice, sheep, rabbits or rats.
13 . The antibody of claim 13 , wherein said antibody is a monoclonal antibody.
14 . The antibody of claim 11 , wherein said antibody is derived from an immunogenic carrier having a reactive amino or thiol group polymer conjugated to a compound selected from the group consisting of compounds of the formula:
wherein B is: —(C═O)—, —(C═O)—NH—, —(C═O)—O—, —CH 2 —;
Y is an organic spacing group;
X is a terminal functional group capable of binding to a polyamine polymer; and
p is an integer from 0 to 1;
or salts thereof:
15 . The antibody of claim 14 , wherein the carrier contains a thiol group and X in the compound which is conjugated to the immunogenic polymer is a functional group capable of reacting with said thiol.
16 . The antibody of claim 15 , wherein X in said compound is
17 . The antibody of claim 16 , wherein Y in said compound is lower alkylene.
18 . The antibody of claim 17 , wherein the immunogenic carrier contains as the functional group:
wherein v is an integer from 1 to 6.
19 . The antibody of claim 18 , wherein said antibody is derived from mice, sheep, rabbits or rats.
20 . A compound of the formula:
wherein B is: —(C═O)—, —(C═O)—NH—, —(C═O)—O—, —CH 2 —;
Y is an organic spacing group;
X is a terminal functional group capable of binding to a polyamine polymer; and
p is an integer from 0 to 1;
or salts thereof.
21 . The compound of claim 20 , wherein p is 0.
22 . The compound of claim 21 , wherein X is
wherein R 3 is hydrogen or taken together with its attached oxygen atom forms a reactive ester and R 4 is oxygen or sulfur.
23 . The compound of claim 22 , wherein X is
and R 3 is hydrogen.
24 . The compound of claim 22 , wherein X is
and OR 3 forms a reactive ester.
25 . The compound of claim 24 , wherein the ester formed is a lower alkyl ester, imidoester or amidoester.
26 . The compound of claim 20 , wherein p is 1.
27 . The compound of claim 25 , wherein X is
wherein R 3 is hydrogen or taken together with its attached oxygen atom forms a reactive ester and R 4 is oxygen or sulfur.
28 . The compound of claim 26 , wherein Y is alkylene containing from 1 to 10 carbon atoms,
wherein n and o are integers from 0 to 6, and m is an integer from 1 to 6.
29 . A conjugate of a carrier having a thiol or amine group with a compound of the formula:
wherein B is: —(C═O)—, —(C═O)—NH—, —(C═O)—O—, —CH 2 —;
Y is an organic spacing group;
X is a terminal functional group capable of binding to a polyamine polymer; and
p is an integer from 0 to 1;
or salts thereof:
30 . The conjugate of claim 29 , wherein p is 0.
31 . The conjugate of claim 30 , wherein p is 1.
32 . The conjugate of claim 31 , wherein Y is alkylene containing from 1 to 10 carbon atoms,
wherein n and o are integers from 0 to 6, and m is an integer from 1 to 6.
33 . The conjugate of claim 32 , wherein the carrier contains an immunogenic polymeric polymer containing one or more amino groups linked by
wherein R 4 is oxygen or sulfur.
34 . A kit for determining the presence of clozapine in a patient sample comprising reagents in separate containers, one of the reagents being a conjugate of a carrier containing a functional amino or thiol group with a compound selected from the groups consisting of compounds of the formula:
wherein B is: —(C═O)—, —(C═O)—NH—, —(C═O)—O—, —CH 2 —;
Y is an organic spacing group;
X is a terminal functional group capable of binding to a polyamine polymer; and
p is an integer from 0 to 1;
or salts thereof; and the second container containing an antibody substantially selectively reactive with clozapine and not substantially cross-reactive to N-desmethylclozapine and clozapine-N-oxide
35 . The kit of claim 34 , wherein said conjugate is present in a predetermined amount in said first container.
36 . The kit of claim 35 , wherein said kit is used to determine the amount of clozapine in said sample.
37 . The kit of claim 37 , wherein said carrier has a reactive terminal functional thiol group and X is a terminal functional group capable of binding to said thiol group.
38 . The kit of claim 38 , wherein X is